![](/img/cover-not-exists.png)
PND45 OCRELIZUMAB IS A COST-EFFECTIVE OPTION FOR RELAPSING MULTIPLE SCLEROSIS PATIENTS, IN IRAN
Ayati, N., Sahraian, M.A., Taheri, S., Nikfar, S.Volume:
22
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.1815
Date:
November, 2019
File:
PDF, 714 KB
2019